(Q55463398)

English

A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

phase I clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Toshihiko Wakabayashi

1

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Takamasa Kayama

2

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Ryo Nishikawa

3

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Hiroshi Takahashi

4

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Naoya Hashimoto

5

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Jun Takahashi

6

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Tomokazu Aoki

7

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Kazuhiko Sugiyama

8

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Masatoshi Ogura

9

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Atsushi Natsume

10

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Jun Yoshida

11

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

publication date

14 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

104

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

2

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

573-577

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

https://scigraph.springernature.com/pub.10.1007/s11060-011-0529-1

0 references

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Genetic pathways to glioblastoma: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Efficacy of post operative adjuvant therapy with human interferon beta, MCNU and radiation (IMR) for malignant glioma: comparison among three protocols.

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0529-1

21 January 2018

IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide

1 reference

https://pubmed.ncbi.nlm.nih.gov/21327711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21327711

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11060-011-0529-1

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 July 2018

http://europepmc.org/abstract/MED/21327711

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55463398&oldid=1749511887"